In the context of the current research, treatment approach for the two subtypes can be varied: subtype 1 could be treated with drugs targeting the tumor-infiltrating immune cells-related pathways (TCR and BCR) and tumor progression-related pathways (p53, JAK-STAT, MAPK, and Notch); subtype 2 could be treated with metabolism-related pathways, particularly tyrosine metabolism, cytochrome p450 metabolism, and arachidonic acid metabolism. The gene discussed is SOAT1; the disease is neoplasm.